GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price looking cheap to me?

Shares of GSK PLC GSK rose 1.79% to £14.47 Thursday, on what proved to be an all-around rough trading session for the stock ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might ...

International biotechnology company GlaxoSmithKline is moving its vaccine and infectious disease research teams to Cambridge, ...

Importantly, our data indicates that GSK's profit was reduced by UK£2.5b, due to unusual items, over the last year. It's ...

The UK's major stock indexes have declined for the third consecutive session, influenced by mixed corporate earnings and ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.